临床IA期非小细胞肺癌患者分期脑MRI无预后影响
本研究回顾性纳入2009年2月至2016年3月行根治性切除的临床T1N0M0非小细胞肺癌患者628例,其中53%行分期脑MRI。多因素分析显示分期脑MRI对无脑转移生存、至脑转移时间和总生存均无预后获益,倾向性评分匹配和逆概率加权后结果一致。
要点
- 临床IA期NSCLC无症状患者行分期脑MRI未显示无脑转移生存获益(HR 1.06,95%CI 0.69-1.63,P=.79)。
- 分期脑MRI对至脑转移时间(HR 1.60,95%CI 0.70-3.94,P=.29)和总生存(HR 0.86,95%CI 0.54-1.37,P=.54)均无显著影响。
- 倾向性评分匹配和逆概率加权后结果一致,支持分期脑MRI对此人群无预后影响。
核心结论
- 无症状临床IA期NSCLC患者行分期脑MRI与未行者相比,无脑转移生存、至脑转移时间和总生存均无差异。
研究设计与样本
- 回顾性纳入2009年2月至2016年3月行根治性切除的临床TNM分期T1N0M0 NSCLC患者628例(平均年龄64岁±10[SD],319例男性),比较行与未行分期脑MRI者,采用Cox回归和Fine-Gray亚分布风险模型多因素调整,并应用倾向性评分匹配和逆概率治疗加权。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Although various guidelines discourage performing brain MRI for staging purposes in asymptomatic patients with clinical stage IA non-small cell lung cancer (NSCLC), evidence regarding their postoperative survival is lacking. Purpose To investigate the survival benefit of performing brain MRI in asymptomatic patients with early-stage NSCLC. Materials and Methods Patients who underwent curative resection between February 2009 and March 2016 for clinical TNM stage T1N0M0 NSCLC were retrospectively included. Patient survival and development of brain metastasis during postoperative surveillance were documented. The cumulative survival rate and incidence of brain metastasis were compared between patients who underwent surgery with or without staging brain MRI by using Cox regression and a Fine-Gray subdistribution hazard model, respectively, for multivariable adjustment. Propensity score matching and inverse probability of treatment weighting were applied for confounder adjustment. Results A total of 628 patients (mean age, 64 years ± 10 [SD]; 319 men) were included, of whom 53% (331 of 628) underwent staging brain MRI. In the multivariable analyses, brain MRI did not show prognostic benefits for brain metastasis-free survival (hazard ratio [HR], 1.06; 95% CI: 0.69, 1.63; P = .79), time to brain metastasis (HR, 1.60; 95% CI: 0.70, 3.94; P = .29), and overall survival (HR, 0.86; 95% CI, 0.54, 1.37; P = .54). Consistent results were obtained after propensity score matching (brain metastasis-free survival [HR, 0.97; 95% CI: 0.60, 1.57; P = .91], time to brain metastasis [HR, 1.29; 95% CI: 0.50, 3.33; P = .60], and overall survival [HR, 0.89; 95% CI: 0.53, 1.51; P = .67]) and inverse probability of treatment weighting. Conclusion No difference was observed between asymptomatic patients with clinical stage IA non-small cell lung cancer who underwent staging brain MRI and those who did not in terms of brain metastasis-free survival, time to brain metastasis, and overall survival. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Bizzi and Pascuzzo in this issue.
引用
- Nam, Hong, Choi, et al. No Prognostic Impact of Staging Brain MRI in Patients with Stage IA Non-Small Cell Lung Cancer. Radiology. 2022. PMID: 35258373. doi:10.1148/radiol.212101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。